Go Pro
NASDAQ:SANA

Sana Biotechnology Q2 2026 Earnings Report

Sana Biotechnology logo
$3.10 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$3.09 -0.01 (-0.32%)
As of 09/18/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sana Biotechnology EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Monday, August 10, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Sana Biotechnology's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sana Biotechnology Earnings Headlines

Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company’s approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines.

Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale. Its research programs have included cell therapies for oncology and autoimmune diseases, as well as approaches involving induced pluripotent stem cells and allogeneic, or donor-derived, therapeutic cells.

Founded in 2018 and headquartered in Seattle, Washington, Sana became a publicly traded company on the Nasdaq under the symbol SANA in 2021. The company’s operations are primarily focused on research and clinical development, with programs being advanced through clinical studies and other development activities. Sana has been led by Chief Executive Officer Steve Harr, who has experience in the biotechnology and pharmaceutical industries.

View Sana Biotechnology Profile